Context Although type 2 diabetes (T2D) is a risk factor for liver fibrosis in nonalcoholic fatty
liver disease (NAFLD), the specific contribution of insulin resistance (IR) relative to other …

In clinical practice, we often deal with patients who suffer from non-alcoholic fatty liver
disease (NAFLD) concurrent with type 2 diabetes mellitus (T2DM). The etiopathogenesis of …

Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly
associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs …

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular …

Association of glucagon-like peptide-1 receptor agonists wit... : Hepatology Association of
glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 …

Current research has described improving multisystem disease and organ function through
dietary nitrate (DN) supplementation. They have provided some evidence that these floras …

Background Metabolic associated fatty liver disease (MAFLD) is a novel terminology
introduced in 2020 to provide a more accurate description of fatty liver disease associated …

Background Patients with nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes
(T2D) or other components of metabolic syndrome are at high risk for disease progression …

Objective We intend to look at the link between remnant cholesterol (RC) and nonalcoholic
fatty liver disease (NAFLD). We hypothesise that there may be a positive and nonlinear …

The incidence and prevalence of non‐alcoholic fatty liver disease (NAFLD) have been
steadily increasing worldwide, with a huge societal and economic burden. Recently, NAFLD …